Skip to main content

Welcome to the pfizer inflammation & immunology pipeline

select a hexagon to explore trials by therapeutic area

bluehex bluehex_click
dermatology
Select a hexagon to learn more

DISEASE
STATE

DERMATOLOGY1,2,a

PHASE 1

PHASE 3

JAK1e,g

INHIBITOR

RECRUITING

PDE4h

INHIBITOR

RECRUITING

DISCOVER OUR PIPELINE COMPOUNDS

Explore the compounds currently under
investigation

KEY DERMATOLOGY COMPOUNDS 1

Ritlecitinib (PF-06651600)

Dermatology disease states under investigation3-7:

Alopecia areata and vitiligo

Crisaborole
PDE4

Inhibitor

Dermatology disease states under investigation8,9,*:

Stasis dermatitis

*Atopic dermatitis is registered in various markets.

Abrocitinib (PF-04965842)
JAK1

Inhibitor

Dermatology disease states under investigation10,11:

Atopic dermatitis

Brepocitinib (PF-06700841)

Dermatology disease states under investigation6,7,12-14:

Alopecia areata, atopic dermatitis, hidradenitis suppurativa, plaque psoriasis, and vitiligo

PF-06826647

Dermatology disease states under investigation14,15:

Hidradenitis suppurativa and plaque psoriasis

PF-06650833

Dermatology disease states under investigation14:

Hidradenitis suppurativa

PF-07038124

Dermatology disease states under investigation2:

Atopic dermatitis and plaque psoriasis

ONGOING CLINICAL TRIALS

Investigate the latest compounds with
ongoing clinical trials

SEE THE LATEST DEVELOPMENTS IN OUR PHASE 3 TRIALS

Phase 3b:

Abrocitinib is an investigational oral JAK1 inhibitor
for atopic dermatitis

Phase 3:

Abrocitinib is an investigational oral JAK1 inhibitor
for atopic dermatitis (JADE EXTEND)

Phase 3:

Crisaborole is a topical PDE4 inhibitor being
evaluated for once daily use in atopic dermatitis

Phase 3:

Ritlecitinib is an investigational oral JAK3/TEC
inhibitor for alopecia areata

LEARN MORE ABOUT OUR OTHER ONGOING TRIALS

Phase 3:

Brepocitinib is an investigational topical
TYK2/JAK1 inhibitor for plaque psoriasis

Phase 2a:

Ritlecitinib is an investigational oral
JAK3/TEC inhibitor for alopecia areata

Phase 2a:

Crisaborole is a topical PDE4 inhibitor under
investigation for stasis dermatitis

Phase 2b:

PF-06650833 is an investigational oral IRAK4
inhibitor,
PF-06826647 is an investigational oral TYK2
inhibitor, and
Brepocitinib is an investigational oral
TYK2/JAK1 inhibitor for hidradenitis suppurativa

Phase 2b:

PF-07038124 is a topical PDE4 inhibitor under investigation
for atopic dermatitis and
plaque psoriasis

gastroenterology
Select a hexagon to learn more

DISEASE
STATE

GASTROENTEROLOGY1,a

PHASE 1

DGAT2

INHIBITOR

COMPLETED

PHASE 3

DISCOVER OUR PIPELINE COMPOUNDS

Explore the compounds currently under
investigation

KEY GASTROENTEROLOGY COMPOUNDS1

Ritlecitinib (PF-06651600)

Dermatology disease states under investigation2-5:

Alopecia areata and vitiligo

Brepocitinib (PF-06700841)

Dermatology disease states under investigation2,3:

Crohn’s disease and ulcerative colitis

Dekavil (PF-06687234; F8-IL 10)

Gastroenterology disease states under investigation4:

Ulcerative colitis

PF-06480605

Gastroenterology disease states under investigation5:

Ulcerative colitis

ONGOING CLINICAL TRIALS

Investigate the latest compounds with
ongoing clinical trials

Phase 2b:

PF-06480605 is an investigational TNFSF15
blocker for ulcerative colitis

Phase 2a:

Brepocitinib is an investigational oral
TYK2/JAK1 inhibitor and ritlecitinib is an
Investigatetional oral JAK3/TEC inhibitor for
Crohn's disease

rheumatology
Select a hexagon to learn more

DISEASE
STATE

RHEUMATOLOGY1,a

PHASE 1

Chemokine

INHIBITOR

RECRUITING

PHASE 2

PHASE 3

JAK1/
JAK3

INHIBITOR

RECRUITING

JAK1/
JAK3f

INHIBITOR

RECRUITING

DISCOVER OUR PIPELINE COMPOUNDS

Explore the compounds currently under
investigation

KEY RHEUMATOLOGY COMPOUNDS1

Tofacitinib
JAK1/
JAK3

Inhibitor

Rheumatology disease states under investigation2-4:

Juvenile idiopathic arthritis, rheumatoid arthritis, and systemic juvenile idiopathic arthritis

Brepocitinib (PF-06700841)

Rheumatology disease states under investigation5,6:

Lupus and psoriatic arthritis

PF-06823859

Rheumatology disease states under investigation7,8:

Dermatomyositis and lupus

Dekavil (PF-06687234; F8-IL 10)

Rheumatology disease states under investigation9:

Rheumatoid arthritis

PF-06650833

Rheumatology disease states under investigation4:

Rheumatoid arthritis

Ritlecitinib (PF-06651600)

Rheumatology disease states under investigation4,10:

Rheumatoid arthritis

ONGOING CLINICAL TRIALS

Investigate the latest compounds with
ongoing clinical trials

SEE THE LATEST DEVELOPMENTS IN OUR PHASE 3 TRIALS

Phase 3:

Tofacitinib is a JAK1/JAK3 inhibitor under
investigation for systemic juvenile idiopathic arthritis

Phase 2/3:

Tofacitinib is a JAK1/JAK3 inhibitor under
investigation for juvenile idiopathic arthritis

LEARN MORE ABOUT OUR OTHER ONGOING TRIALS

Phase 2b:

Brepocitinib is an investigational oral TYK2/JAK1 inhibitor for lupus

Phase 2:

PF-06650833 is an investigational oral IRAK4
inhibitor,
ritlecitinib is an investigational oral JAK3/TEC
inhibitor, and
tofacitiniba is a JAK1/JAK3 inhibitor under
investigation alone and in combination with
PF-06650833 for rheumatoid arthritis

Phase 2:

PF-06823859 in an investigational IFNB1 blocker for dermatomyositis and lupus

Phase 1:

PF-06835375 in an investigational chemokine
inhibitor for lupus

ADVANCING RESEARCH WITH THE GOAL OF LIFE-CHANGING IMPACT

Are you a healthcare professional?

The information on this site is intended for U.S. healthcare professionals.